The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF-κB signaling pathway

The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive c...

Full description

Saved in:
Bibliographic Details
Published inFood & function Vol. 14; no. 7; pp. 3155 - 3168
Main Authors Li, Guo-li, Tang, Jia-feng, Tan, Wen-li, Zhang, Tao, Zeng, Di, Zhao, Shuang, Ran, Jian-hua, Li, Jing, Wang, Ya-ping, Chen, Di-long
Format Journal Article
LanguageEnglish
Published England Royal Society of Chemistry 03.04.2023
Subjects
Online AccessGet full text
ISSN2042-6496
2042-650X
2042-650X
DOI10.1039/D2FO02191A

Cover

Abstract The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum , a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo . In vitro , the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling.
AbstractList The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum , a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo . In vitro , the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling.
The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo. In vitro, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling.
The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. polysaccharide (GLPS) is a major bioactive component of , a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group . , the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling.
The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo. In vitro, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling.The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages reach the M1 or M2 activation state according to their respective environment. Ganoderma lucidum polysaccharide (GLPS) is a major bioactive component of Ganoderma lucidum, a well-known medicinal mushroom. Although the immunomodulatory and anti-tumor effects of GLPS have been proven, GLPS's effect on inhibiting hepatocellular carcinoma (HCC) by regulating macrophage polarization is little known. Our data showed that GLPS notably inhibited the growth of a Hepa1-6 allograft. The expression of M1 marker CD86 was higher in the tumor tissue of the GLPS treatment group than in the control group in vivo. In vitro, the phagocytic activity and NO production of macrophages were increased by GLPS treatment. Moreover, it was discovered that GLPS was able to increase the expression of the M1 phenotype marker CD86, iNOS, and pro-inflammatory cytokines comprising IL-12a, IL-23a, IL-27 and TNF-α, but inhibited macrophage polarization towards the M2 phenotype by decreasing the expression of CD206, Arg-1, and inflammation-related cytokines comprising IL-6 and IL-10. The data suggest that GLPS may regulate macrophage polarization. Mechanistically, GLPS increased the phosphorylation of MEK and ERK. In addition, the phosphorylation of IκBα and P65 was increased by GLPS treatment. These data showed that GLPS can regulate the MAPK/NF-κB signaling pathway responsible for M1 polarization. In a nutshell, our research puts forward a new application of GLPS in anti-HCC treatment by regulating macrophage polarization through activating MAPK/NF-κB signaling.
Author Zhao, Shuang
Wang, Ya-ping
Tan, Wen-li
Zeng, Di
Tang, Jia-feng
Li, Jing
Chen, Di-long
Li, Guo-li
Zhang, Tao
Ran, Jian-hua
Author_xml – sequence: 1
  givenname: Guo-li
  orcidid: 0000-0002-4983-1441
  surname: Li
  fullname: Li, Guo-li
  organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China
– sequence: 2
  givenname: Jia-feng
  surname: Tang
  fullname: Tang, Jia-feng
  organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China
– sequence: 3
  givenname: Wen-li
  surname: Tan
  fullname: Tan, Wen-li
  organization: Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China
– sequence: 4
  givenname: Tao
  surname: Zhang
  fullname: Zhang, Tao
  organization: Neuroscience Research Center, College of Basic Medicine, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China
– sequence: 5
  givenname: Di
  surname: Zeng
  fullname: Zeng, Di
  organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China
– sequence: 6
  givenname: Shuang
  surname: Zhao
  fullname: Zhao, Shuang
  organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China
– sequence: 7
  givenname: Jian-hua
  surname: Ran
  fullname: Ran, Jian-hua
  organization: Neuroscience Research Center, College of Basic Medicine, Chongqing Medical University, Chongqing, PR China
– sequence: 8
  givenname: Jing
  surname: Li
  fullname: Li, Jing
  organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China
– sequence: 9
  givenname: Ya-ping
  surname: Wang
  fullname: Wang, Ya-ping
  organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China
– sequence: 10
  givenname: Di-long
  surname: Chen
  fullname: Chen, Di-long
  organization: Lab of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, PR China, Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, PR China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36883482$$D View this record in MEDLINE/PubMed
BookMark eNptkc9u1DAQxi1UREvphQdAlrggpFDHTrz2cSlsQRTKoUjcoon_bFwldmonoOVleA8egmfCoV0hVfgy1uj3fTP65jE68MEbhJ6W5FVJmDx9QzeXhJayXD9AR5RUtOA1-Xqw_1eSH6KTlK5JfkxKIcUjdMi4EKwS9Aj9vOoMBj-5ojMjTEGZvp97iFhBVM6HAbCx1qgp4WDxGPpdAqU6iE6bhG0MAz4HH7SJmexn5fQ84HaHo9lmm8n5LR5AxTB2sDWLPit_5H7w-JsDPOXpH9efP5x-2hS_f73GyW099IsqL9N9h90T9NBCn8zJXT1GXzZvr87eFReX5-_P1heFYnU5FYxpQ63k0FqqeClsbaq2JURz1dblijMtW0IFh8zp1ubKiVErJSjXSrGKHaMXt75jDDezSVMzuLSEAd6EOTV0JSrBZC1FRp_fQ6_DHPPaCyWZpDWXMlPP7qi5HYxuxugGiLtmH30GyC2Q00kpGtsoN_1NZorg-qYkzXLg5t-Bs-TlPcne9T_wH4CSqKA
CitedBy_id crossref_primary_10_1016_j_apsb_2024_05_032
crossref_primary_10_1016_j_fitote_2024_106150
crossref_primary_10_1016_j_biopha_2024_116161
crossref_primary_10_3390_molecules28196816
crossref_primary_10_1016_j_ijbiomac_2024_134757
crossref_primary_10_12677_ACM_2023_1381829
crossref_primary_10_1016_j_ijbiomac_2024_138575
crossref_primary_10_3390_nu16111642
crossref_primary_10_3390_foods13172665
crossref_primary_10_3390_foods13101578
crossref_primary_10_1016_j_ijbiomac_2024_138513
crossref_primary_10_1039_D3FO04166B
crossref_primary_10_1016_j_ijbiomac_2024_133171
crossref_primary_10_1016_j_ijbiomac_2025_140645
crossref_primary_10_3892_ol_2024_14796
crossref_primary_10_1038_s41598_025_86977_x
crossref_primary_10_3390_ijms26062684
crossref_primary_10_1002_eji_202451139
crossref_primary_10_1016_j_heliyon_2023_e17116
Cites_doi 10.1016/j.addr.2017.04.010
10.2147/JIR.S307801
10.1002/kjm2.12020
10.1016/S1471-4906(02)02302-5
10.2147/JHC.S300165
10.1007/s00441-014-2083-6
10.1002/hep.26754
10.1016/j.ijbiomac.2015.10.088
10.3389/fimmu.2021.642842
10.3390/molecules23030649
10.1016/B978-0-12-417028-5.00006-5
10.3390/ijms22136894
10.1186/s12967-015-0465-5
10.3109/1061186X.2012.697167
10.1016/j.coph.2017.04.007
10.4254/wjh.v7.i2.165
10.1038/nm.3394
10.1038/ni.1990
10.1039/D0BM01142H
10.1186/s13075-021-02512-z
10.1016/j.chemosphere.2017.08.070
10.3389/fimmu.2021.660065
10.1177/1534735418762537
10.3390/cells9010046
10.1016/j.phymed.2022.154228
10.4161/auto.23546
10.1016/j.carbpol.2018.10.028
10.1080/2162402X.2021.1897295
10.1016/j.jconrel.2016.07.018
10.1172/JCI59643
10.3390/ijms22105196
10.2478/v10007-011-0030-6
10.1002/ptr.4980
10.4049/jimmunol.169.5.2253
ContentType Journal Article
Copyright Copyright Royal Society of Chemistry 2023
Copyright_xml – notice: Copyright Royal Society of Chemistry 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7T7
7TO
7U7
8FD
C1K
FR3
H94
P64
7X8
DOI 10.1039/D2FO02191A
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Oncogenes and Growth Factors Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
Technology Research Database
Toxicology Abstracts
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList CrossRef
Oncogenes and Growth Factors Abstracts
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Diet & Clinical Nutrition
EISSN 2042-650X
EndPage 3168
ExternalDocumentID 36883482
10_1039_D2FO02191A
Genre Journal Article
GroupedDBID ---
0-7
0R~
4.4
53G
705
7~J
AAEMU
AAHBH
AAIWI
AAJAE
AANOJ
AARTK
AAWGC
AAXHV
AAYXX
ABASK
ABDVN
ABEMK
ABJNI
ABPDG
ABRYZ
ABXOH
ACGFS
ACLDK
ACPRK
ADMRA
ADSRN
AEFDR
AENEX
AENGV
AESAV
AETIL
AFLYV
AFOGI
AFRAH
AFRZK
AFVBQ
AGEGJ
AGRSR
AHGCF
AKBGW
AKMSF
ALMA_UNASSIGNED_HOLDINGS
ANUXI
APEMP
ASKNT
AUDPV
AZFZN
BLAPV
BSQNT
C6K
CITATION
EBS
ECGLT
EE0
EF-
GGIMP
H13
HZ~
H~N
J3I
O-G
O9-
P2P
RAOCF
RCNCU
RNS
RPMJG
RSCEA
RVUXY
SKF
SKH
SKJ
SKM
SKR
SKZ
SLC
SLF
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7T7
7TO
7U7
8FD
C1K
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c351t-33de2f96abf2c618f5e4bb00d6cb51763d9b0286a3dedbf6a360ec7c826dcc343
ISSN 2042-6496
2042-650X
IngestDate Sat Sep 27 21:10:58 EDT 2025
Mon Jun 30 12:05:25 EDT 2025
Thu Apr 03 07:12:34 EDT 2025
Tue Jul 01 03:02:52 EDT 2025
Thu Apr 24 23:00:19 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c351t-33de2f96abf2c618f5e4bb00d6cb51763d9b0286a3dedbf6a360ec7c826dcc343
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-4983-1441
OpenAccessLink https://pubs.rsc.org/en/content/articlepdf/2023/fo/d2fo02191a
PMID 36883482
PQID 2793925699
PQPubID 2047526
PageCount 14
ParticipantIDs proquest_miscellaneous_2784839598
proquest_journals_2793925699
pubmed_primary_36883482
crossref_citationtrail_10_1039_D2FO02191A
crossref_primary_10_1039_D2FO02191A
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-04-03
PublicationDateYYYYMMDD 2023-04-03
PublicationDate_xml – month: 04
  year: 2023
  text: 2023-04-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Cambridge
PublicationTitle Food & function
PublicationTitleAlternate Food Funct
PublicationYear 2023
Publisher Royal Society of Chemistry
Publisher_xml – name: Royal Society of Chemistry
References Zhuang (D2FO02191A/cit24/1) 2021; 8
Francisco (D2FO02191A/cit19/1) 2021; 12
Heindryckx (D2FO02191A/cit11/1) 2015; 7
Zhu (D2FO02191A/cit20/1) 2019; 35
Joseph (D2FO02191A/cit12/1) 2011; 61
Sun (D2FO02191A/cit15/1) 2012; 20
Zeng (D2FO02191A/cit1/1) 2022; 103
Lu (D2FO02191A/cit35/1) 2021; 23
He (D2FO02191A/cit37/1) 2021; 22
Han (D2FO02191A/cit39/1) 2018; 191
Zhang (D2FO02191A/cit13/1) 2019; 205
Lang (D2FO02191A/cit31/1) 2002; 169
Sica (D2FO02191A/cit33/1) 2012; 122
Dehne (D2FO02191A/cit3/1) 2017; 35
Artemova (D2FO02191A/cit26/1) 2021; 22
Degroote (D2FO02191A/cit5/1) 2018
Pan (D2FO02191A/cit34/1) 2021; 14
Locati (D2FO02191A/cit29/1) 2013; 120
Mantovani (D2FO02191A/cit7/1) 2002; 23
Lu (D2FO02191A/cit17/1) 2014; 28
Wang (D2FO02191A/cit21/1) 2018; 17
Ngambenjawong (D2FO02191A/cit23/1) 2017; 114
Cor (D2FO02191A/cit22/1) 2018; 23
Avila-Ponce de Leon (D2FO02191A/cit25/1) 2021; 12
Sica (D2FO02191A/cit28/1) 2014; 59
Krausgruber (D2FO02191A/cit32/1) 2011; 12
Anfray (D2FO02191A/cit8/1) 2019; 9
Prabhu (D2FO02191A/cit2/1) 2021; 9
Chang (D2FO02191A/cit38/1) 2013; 9
Liu (D2FO02191A/cit16/1) 2016; 82
Mantovani (D2FO02191A/cit30/1) 2002; 23
Quail (D2FO02191A/cit27/1) 2013; 19
Capece (D2FO02191A/cit10/1) 2013
Lee (D2FO02191A/cit4/1) 2013; 1835
Li (D2FO02191A/cit14/1) 2015; 13
Lee (D2FO02191A/cit9/1) 2016; 240
Sun (D2FO02191A/cit18/1) 2015; 360
He (D2FO02191A/cit36/1) 2021; 10
Ngambenjawong (D2FO02191A/cit6/1) 2017; 114
References_xml – volume: 114
  start-page: 206
  year: 2017
  ident: D2FO02191A/cit23/1
  publication-title: Adv. Drug Delivery Rev.
  doi: 10.1016/j.addr.2017.04.010
– volume: 14
  start-page: 2045
  year: 2021
  ident: D2FO02191A/cit34/1
  publication-title: J. Inflammation Res.
  doi: 10.2147/JIR.S307801
– volume: 35
  start-page: 222
  year: 2019
  ident: D2FO02191A/cit20/1
  publication-title: Kaohsiung J. Med. Sci.
  doi: 10.1002/kjm2.12020
– volume: 23
  start-page: 549
  year: 2002
  ident: D2FO02191A/cit30/1
  publication-title: Trends Immunol.
  doi: 10.1016/S1471-4906(02)02302-5
– volume: 8
  start-page: 599
  year: 2021
  ident: D2FO02191A/cit24/1
  publication-title: J. Hepatocell. Carcinoma
  doi: 10.2147/JHC.S300165
– volume: 360
  start-page: 379
  year: 2015
  ident: D2FO02191A/cit18/1
  publication-title: Cell Tissue Res.
  doi: 10.1007/s00441-014-2083-6
– volume: 59
  start-page: 2034
  year: 2014
  ident: D2FO02191A/cit28/1
  publication-title: Hepatology
  doi: 10.1002/hep.26754
– volume: 82
  start-page: 973
  year: 2016
  ident: D2FO02191A/cit16/1
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2015.10.088
– volume: 23
  start-page: 549
  year: 2002
  ident: D2FO02191A/cit7/1
  publication-title: Trends Immunol.
  doi: 10.1016/S1471-4906(02)02302-5
– volume: 12
  start-page: 642842
  year: 2021
  ident: D2FO02191A/cit25/1
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.642842
– start-page: 7819520
  year: 2018
  ident: D2FO02191A/cit5/1
  publication-title: J. Immunol. Res.
– volume: 23
  start-page: 649
  year: 2018
  ident: D2FO02191A/cit22/1
  publication-title: Molecules
  doi: 10.3390/molecules23030649
– volume: 120
  start-page: 163
  year: 2013
  ident: D2FO02191A/cit29/1
  publication-title: Adv. Immunol.
  doi: 10.1016/B978-0-12-417028-5.00006-5
– volume: 114
  start-page: 206
  year: 2017
  ident: D2FO02191A/cit6/1
  publication-title: Adv. Drug Delivery Rev.
  doi: 10.1016/j.addr.2017.04.010
– volume: 22
  start-page: 6894
  year: 2021
  ident: D2FO02191A/cit37/1
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22136894
– volume: 13
  start-page: 100
  year: 2015
  ident: D2FO02191A/cit14/1
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-015-0465-5
– volume: 20
  start-page: 582
  year: 2012
  ident: D2FO02191A/cit15/1
  publication-title: J. Drug Targeting
  doi: 10.3109/1061186X.2012.697167
– volume: 35
  start-page: 12
  year: 2017
  ident: D2FO02191A/cit3/1
  publication-title: Curr. Opin. Pharmacol.
  doi: 10.1016/j.coph.2017.04.007
– volume: 7
  start-page: 165
  year: 2015
  ident: D2FO02191A/cit11/1
  publication-title: World J. Hepatol.
  doi: 10.4254/wjh.v7.i2.165
– volume: 19
  start-page: 1423
  year: 2013
  ident: D2FO02191A/cit27/1
  publication-title: Nat. Med.
  doi: 10.1038/nm.3394
– volume: 12
  start-page: 231
  year: 2011
  ident: D2FO02191A/cit32/1
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.1990
– volume: 9
  start-page: 506
  year: 2021
  ident: D2FO02191A/cit2/1
  publication-title: Biomater. Sci.
  doi: 10.1039/D0BM01142H
– volume: 23
  start-page: 142
  year: 2021
  ident: D2FO02191A/cit35/1
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-021-02512-z
– volume: 191
  start-page: 1056
  year: 2018
  ident: D2FO02191A/cit39/1
  publication-title: Chemosphere
  doi: 10.1016/j.chemosphere.2017.08.070
– volume: 12
  start-page: 660065
  year: 2021
  ident: D2FO02191A/cit19/1
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.660065
– volume: 17
  start-page: 674
  year: 2018
  ident: D2FO02191A/cit21/1
  publication-title: Integr. Cancer Ther.
  doi: 10.1177/1534735418762537
– volume: 9
  start-page: 46
  year: 2019
  ident: D2FO02191A/cit8/1
  publication-title: Cells
  doi: 10.3390/cells9010046
– start-page: 187204
  year: 2013
  ident: D2FO02191A/cit10/1
  publication-title: BioMed Res. Int.
– volume: 103
  start-page: 154228
  year: 2022
  ident: D2FO02191A/cit1/1
  publication-title: Phytomedicine
  doi: 10.1016/j.phymed.2022.154228
– volume: 9
  start-page: 619
  year: 2013
  ident: D2FO02191A/cit38/1
  publication-title: Autophagy
  doi: 10.4161/auto.23546
– volume: 1835
  start-page: 170
  year: 2013
  ident: D2FO02191A/cit4/1
  publication-title: Biochim. Biophys. Acta
– volume: 205
  start-page: 192
  year: 2019
  ident: D2FO02191A/cit13/1
  publication-title: Carbohydr. Polym.
  doi: 10.1016/j.carbpol.2018.10.028
– volume: 10
  start-page: 1897295
  year: 2021
  ident: D2FO02191A/cit36/1
  publication-title: OncoImmunology
  doi: 10.1080/2162402X.2021.1897295
– volume: 240
  start-page: 527
  year: 2016
  ident: D2FO02191A/cit9/1
  publication-title: J. Controlled Release
  doi: 10.1016/j.jconrel.2016.07.018
– volume: 122
  start-page: 787
  year: 2012
  ident: D2FO02191A/cit33/1
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI59643
– volume: 22
  start-page: 5196
  year: 2021
  ident: D2FO02191A/cit26/1
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22105196
– volume: 61
  start-page: 335
  year: 2011
  ident: D2FO02191A/cit12/1
  publication-title: Acta Pharm.
  doi: 10.2478/v10007-011-0030-6
– volume: 28
  start-page: 200
  year: 2014
  ident: D2FO02191A/cit17/1
  publication-title: Phytother. Res.
  doi: 10.1002/ptr.4980
– volume: 169
  start-page: 2253
  year: 2002
  ident: D2FO02191A/cit31/1
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.169.5.2253
SSID ssj0000399898
Score 2.467121
Snippet The response of macrophages to environmental signals demonstrates its heterogeneity and plasticity. After different forms of polarized activation, macrophages...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 3155
SubjectTerms Anticancer properties
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
CD86 antigen
Cell activation
Cytokines
Cytokines - metabolism
Ganoderma lucidum
Hepatocellular carcinoma
Heterogeneity
Immunomodulation
Inflammation
Interleukin 10
Interleukin 27
Interleukin 6
Liver cancer
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Macrophages
MAP kinase
Mushrooms
NF-kappa B - metabolism
NF-κB protein
Nitric-oxide synthase
Phagocytes
Phenotypes
Phosphorylation
Polarization
Polysaccharides
Polysaccharides - metabolism
Polysaccharides - pharmacology
Reishi - metabolism
Saccharides
Signal Transduction
Signaling
Tumor necrosis factor-α
Tumors
Title The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF-κB signaling pathway
URI https://www.ncbi.nlm.nih.gov/pubmed/36883482
https://www.proquest.com/docview/2793925699
https://www.proquest.com/docview/2784839598
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF6F9MIF8U9KQYugSKgyTby24z0mbdICacrBkXKzdte2aimxoyYGlZfhPbjwBjwTM_b6Jygg4OJE9mhjeb7s_PibGUJeBcy1mBn1jQhDFMtxIkOKLjdkZIeyq1zXzptVX0yd85n1fm7PW63vDdZStpFv1ZeddSX_o1U4B3rFKtl_0Gy1KJyA76BfOIKG4fjXOoYnExtXYFQ2KSbhc1apwgFBSboUTbrGKl3crIXCMqs4CNdFYcmZSHAYGkguMhUH2RLd0etiPj0mEZYCR3xdIbFnhUGwrto8-hSL3GW9GHz8APc_HRuHJ6PD4WB4hIQQUdS4g3P5WWy9Nh5jD2UEG5rTJgXgLEsNXagdV6SeWBhRWOxFntAWNn-JlGhZr4Z2lfj2RNrMZJgsJ8CwCntFvqQkq-ZkFD3yrt4TTawmciyuu2c3ztnd-dambjXA22_s0KxXtAXW1h7ndu20JF2GjVgDM0rBC-K9hr0sOQLTS388m0x8bzT3bpE9sw_OW5vsDUbeu0mV5oNlcEInjjgsb71sksv4cb38tlv0m1gn93m8u-SODlbooEDePdIKk_ukcwpPjr6muqPsgk7LgQ4PyFdAJN2BSFohkmpE0jSivyCSIiJphUiqEUnlDa0RSWtE0iYiKSCSAiIpIvIY8Pjj25BWWKQaiw_JbDzyTs4NPQLEUMzubQzGgtCMuCNkZCqn58IOYkmwFIGjpN0D2xhwCR6yI0AukBF8Ot1Q9RUEzYFSzGKPSDtJk_AJoU6IdG7mujK0LYlTHMBbVSbGB3DBijrkTakBX-n--DimZeHnPA3G_VNzfJlra9AhLyvZVdEVZqfUQalIX-8aa98Eg8ghzuC8Q15UlwHnqBGRhGmGMq4FgYvN3Q55XACg-hnmuC42pNr_8-JPye36L3ZA2pvrLHwG7vNGPtcQ_QlDlMxr
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+anti-hepatocellular+carcinoma+effects+of+polysaccharides+from+Ganoderma+lucidum+by+regulating+macrophage+polarization+via+the+MAPK%2FNF-%CE%BAB+signaling+pathway&rft.jtitle=Food+%26+function&rft.au=Guo-li%2C+Li&rft.au=Jia-feng%2C+Tang&rft.au=Wen-li%2C+Tan&rft.au=Zhang%2C+Tao&rft.date=2023-04-03&rft.pub=Royal+Society+of+Chemistry&rft.issn=2042-6496&rft.eissn=2042-650X&rft.volume=14&rft.issue=7&rft.spage=3155&rft.epage=3168&rft_id=info:doi/10.1039%2Fd2fo02191a&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2042-6496&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2042-6496&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2042-6496&client=summon